SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.

The company has entered into a major licensing deal with AstraZeneca for its self-developed PDE3/4 inhibitor, TQC3721. Under the agreement, AstraZeneca will pay an upfront fee of US$200 million and could pay up to US$1.7 billion in milestone payments, plus tiered royalties. This marks SBP GROUP's second major licensing agreement with a multinational pharmaceutical corporation this year, demonstrating strong recognition of its internal R&D and innovation capabilities.

Simultaneously, SBP GROUP has deepened its strategic partnership with GSK, securing the commercialization rights for two of GSK's major respiratory drugs in mainland China. This dual partnership development, covering both significant upfront payments and expanded commercial opportunities, has provided substantial positive sentiment for the company's growth prospects.